1. A method of controlling an augmented reality object, the method comprising:
receiving, at a computing device, an initialization image captured by an image capture device, the initialization image depicting a background and being free of foreground objects positioned between the background and the image capture device;
receiving, at the computing device, a plurality of subsequent images captured by the image capture device over a period of time, the plurality of subsequent images depicting the background and a foreground object, the foreground object being positioned between the background and the image capture device;
comparing, using the computing device, the initialization image to the plurality of subsequent images to determine positioning of the foreground object over the period of time; and
controlling an augmented reality object being displayed by the computing device based on the positioning of the foreground object over the period of time.
2. The method of claim 1, further comprising analyzing the positioning of the foreground object over the period of time to determine movement associated with the foreground object.
3. The method of claim 2, wherein controlling the augmented reality object comprises controlling the augmented reality object in accordance with the movement.
4. The method of claim 1, wherein comparing the initialization image to the plurality of subsequent images comprises adjusting the subsequent images to account for movement of the image capture device relative to the background such that the comparing is not affected by the movement.
5. The method of claim 1, wherein determining positioning of the foreground object comprises generating a foreground map based on differences between the initialization image and the subsequent images.
6. The method of claim 5, wherein the foreground map describes, for pixels in the plurality of subsequent images, a likelihood that the pixels are part of the foreground object versus the background.
7. The method of claim 6, wherein the likelihood that the pixels are part of the foreground object versus the background is based in part on expected information about the foreground object.
8. The method of claim 7, wherein the expected information about the foreground object comprises ranges of skin colors.
9. The method of claim 7, wherein the expected information about the foreground object comprises shape information.
10. The method of claim 7, wherein the expected information about the foreground object comprises likely regions where the foreground object will be positioned.
11. The method of claim 5, further comprising analyzing the foreground map over the period of time to determine a gesture performed by the foreground object.
12. The method of claim 11, wherein controlling the augmented reality object comprises controlling the augmented reality object in accordance with the gesture.
13. The method of claim 1, further comprising generating an updated initialization image that includes changes in the background, and wherein comparisons occurring after generation of the updated initialization image use the updated initialization image.
14. A system comprising:
one or more processors;
an image capture device to capture two-dimensional images;
an image processing module executing on at least one of the one or more processors to receive an initialization image from the image capture device, receive a subsequent image from the image capture device, analyze the subsequent image to detect a control object that was not present in the initialization image, and determine a location of the control object; and
an augmented reality module executing on at least one of the one or more processors to manipulate an augmented reality object based on the location of the control object.
15. A non-transitory computer-readable storage medium storing instructions that, when executed by a processor, cause the processor to:
receive an initialization image and subsequent interaction images from a two-dimensional image capture device, the subsequent interaction images including a control object that is not present in the initialization image;
determine movements of the control object based on differences between the initialization image and the subsequent interaction images; and
control an augmented reality object displayed by the computing device in response to the movements of the control object.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for inhibiting Interstitial Cystitis and its symptoms in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising a heparinoid, a local anesthetic agent and a buffering compound, thereby inhibiting Interstitial Cystitis and its symptoms in the subject.
2. The method of claim 1 further comprising administering to said subject an effective amount of an osmolar component.
3. The method of claim 2, wherein the composition is in solution and the osmolar component is present in a sufficient amount so that the final solution is isotonic or near isotonic.
4. The method of claim 3, wherein the osmolar component is at least one of sodium chloride, dextrose, dextran 40, dextran 60, starch and mannitol or a combination thereof.
5. The method of claim 1, wherein the local anesthetic agent is at least one of lidocaine, bupivacaine, and mepivacaine.
6. The method of claim 1, wherein the heparinoid comprises at least one of a heparin, a pentosan polysulfate sodium, a heparan sulfate, a heparin sodium, a hyaluronic acid, and a chondroitin sulfate.
7. The method of claim 6, wherein the heparinoid comprises at least one of a heparin, a heparan sulfate, a heparin sodium, a hyaluronic acid, and a chondroitin sulfate, and the method further comprises the administration to said subject of an effective amount of sodium pentosan polysulfate to inhibit Interstitial Cystitis.
8. The method of claim 7, wherein the sodium pentosan polysulfate is administered orally.
9. The method of claim 8, wherein the sodium pentosan polysulfate is in a quantity from about 100 mgday to about 600 mgday.
10. The method of claim 9, wherein the sodium pentosan polysulfate is in a quantity from about 100 mgday to about 300 mgday.
11. A method for repairing a mucin layer of bladder tissue by the method of claim 1 thereby inhibiting Interstitial Cystitis.
12. The method of claim 1, wherein the buffering compound comprises at least one of sodium bicarbonate and THAM (tromethamine or Tris hydroxymethylpropyl).
13. The method of claim 1, wherein the effective amount of the buffering compound is 3 ml of 8.4% sodium bicarbonate (wv) per unit dose.
14. The method of claim 1, wherein the effective amount of the heparinoid is
(i) about 0.5 mg to about 1000 mg of heparin per unit dose;
(ii) about 1 mg to about 600 mg of pentosan polysulfate sodium per unit dose;
(iii) about 0.5 mg to about 10,000 mg of heparan sulfate per unit dose;
(iv) about 5 mg to about 600 mg of hyaluronic acid per unit dose;
(v) about 1 mg to about 10,000 mg of chondroitin sulfate per unit dose; or
(vi) about 10 mg to about 600 mg of heparin sodium per unit dose.
15. The method of claim 1, wherein the effective amount of the anesthetic agent is 10 ml of 1% lidocaine or 16 ml of 2% lidocaine per unit dose.
16. The method of claim 1, wherein the heparinoid, the anesthetic agent, and the buffering compound are administered concomitantly or in sequence.
17. The method of claim 2, wherein the heparinoid, the anesthetic agent, the buffering compound and the osmolar component are administered concomitantly or in sequence.
18. The method of claim 1, wherein the subject is selected from the group consisting of human, monkey, ape, dog, cat, cow, horse, rabbit, mouse and rat subjects.
19. The method of claim 1, wherein administration to said subject is effected by intravesicular administration, administration using liposomes, administration using biodegradable polymers, or administration using a hydrogel.
20. The method of claim 2, wherein the heparinoid, the anesthetic agent, the buffering compound and the osmolar component are in solution.
21. The method of claim 20, wherein the solution has a pH from about 7 to 12.
22. A method for monitoring the course of Interstitial Cystitis in a subject, said method comprising
intravesicularly administering a solution containing an amount of potassium that would elicit pain in a subject that has a compromised urothelium, wherein the subject has been administered the composition, comprising a heparinoid, a local anesthetic agent, and a buffering compound, and
monitoring the pain response of the subject at different points in time,
whereby a difference in the amount of pain determined is indicative of the course of the Interstitial Cystitis condition.